Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at Chardan Capital to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

KLRS has been the subject of a number of other research reports. Wall Street Zen raised Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday. Raymond James Financial started coverage on shares of Kalaris Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating for the company. Finally, Citizens Jmp started coverage on shares of Kalaris Therapeutics in a research note on Monday, November 3rd. They set a “market outperform” rating and a $20.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $14.00.

Kalaris Therapeutics Trading Down 4.0%

Shares of Kalaris Therapeutics stock opened at $9.66 on Tuesday. The firm’s 50 day simple moving average is $6.20 and its two-hundred day simple moving average is $4.45. The firm has a market capitalization of $180.64 million, a price-to-earnings ratio of -2.56 and a beta of -0.04. Kalaris Therapeutics has a 12-month low of $2.14 and a 12-month high of $12.90.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.02.

Institutional Investors Weigh In On Kalaris Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Belpointe Asset Management LLC acquired a new stake in shares of Kalaris Therapeutics during the 3rd quarter worth approximately $231,000. Johnson Financial Group Inc. acquired a new stake in Kalaris Therapeutics during the third quarter valued at $58,000. Bridgeway Capital Management LLC purchased a new position in Kalaris Therapeutics in the third quarter valued at $130,000. Woodline Partners LP purchased a new position in Kalaris Therapeutics in the third quarter valued at $1,394,000. Finally, Fortis Capital Advisors LLC purchased a new position in Kalaris Therapeutics in the third quarter valued at $231,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.